Szczepan Baran

Szczepan Baran

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAdeline C. Y. Chua
Adeline C. Y. Chua
JOJessica Jie Ying Ong
Jessica Jie Ying Ong
Benoit MalleretBenoit Malleret
Benoit Malleret
RSRossarin Suwanarusk
Rossarin Suwanarusk
VKVarakorn Kosaisavee
Varakorn Kosaisavee
PBPablo Bifani
Pablo Bifani
The ability to culture pathogenic organisms substantially enhances the quest for fundamental knowledge and the development of vaccines and drugs. Thus, the elaboration of a protocol for the in vitro cultivation of the erythrocytic stages of Plasmodium falciparum revolutionized research on this important parasite. However, for P. vivax, the most widely distributed and difficult to treat malaria parasite, a strict preference for reticulocytes thwarts efforts to maintain it in vitro. Cultivation of P. cynomolgi, a macaque-infecting species phylogenetically close to P. vivax, was briefly reported in the early 1980s, but not pursued further. Here, we define the conditions under which P. cynomolgi can be adapted to long term in vitro culture to yield parasites that share many of the morphological and phenotypic features of P. vivax. We further validate the potential of this culture system for high-throughput screening to prime and accelerate anti-P. vivax drug discovery efforts.

Verified
Journal Article
Open access
PDF file
BBBabatunde Bello
Babatunde Bello
YBYogesh N. Bundey
Yogesh N. Bundey
RBRoshan Bhave
Roshan Bhave
MKMaksim Khotimchenko
Maksim Khotimchenko
SBSzczepan Baran
Szczepan Baran
JVJyotika Varshney
Jyotika Varshney
The COVID-19 pandemic has presented an unprecedented challenge to the healthcare system. Identifying the genomics and clinical biomarkers for effective patient stratification and management is critical to controlling the spread of the disease. Omics datasets provide a wealth of information that can aid in understanding the underlying molecular mechanisms of COVID-19 and identifying potential biomarkers for patient stratification. Artificial intelligence (AI) and machine learning (ML) algorithms have been increasingly used to analyze large-scale omics and clinical datasets for patient stratification. In this manuscript, we demonstrate the recent advances and predictive accuracies in AI- and ML-based patient stratification modeling linking omics and clinical biomarker datasets, focusing on COVID-19 patients. Our ML model not only demonstrates that clinical features are enough of an indicator of COVID-19 severity and survival, but also infers what clinical features are more impactful, which makes our approach a useful guide for clinicians for prioritization best-fit therapeutics for a given cohort of patients. Moreover, with weighted gene network analysis, we are able to provide insights into gene networks that have a significant association with COVID-19 severity and clinical features. Finally, we have demonstrated the importance of clinical biomarkers in identifying high-risk patients and predicting disease progression.

6 June 2024 in Drug Discovery Today
Verified
Journal Article
Closed access
WTWeida Tong
Weida Tong
SBSzczepan Baran
Szczepan Baran

1 March 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
BBBabatunde Bello
Babatunde Bello
YBYogesh Naren Bundey
Yogesh Naren Bundey
RBRoshan Bhave
Roshan Bhave
MKMaksim Khotimchenko
Maksim Khotimchenko
SBSzczepan Baran
Szczepan Baran
JVJyotika Varshney
Jyotika Varshney
The COVID-19 pandemic has presented an unprecedented challenge to the healthcare system. Identifying the genomics and clinical biomarkers for effective patient stratification and management is critical to controlling the spread of the disease. Omics datasets provide a wealth of information that can aid in understanding the underlying molecular mechanisms of COVID-19 and identifying potential biomarkers for patient stratification. Artificial intelligence (AI) and machine learning (ML) algorithms have been increasingly used to analyze large-scale omics and clinical datasets for patient stratification. In this manuscript, we demonstrate the recent advances and predictive accuracies in AI and ML-based patient stratification modeling linking omics and clinical biomarker datasets, focusing on COVID-19 patients. Our ML model not only demonstrates that clinical features are enough an indicator of COVID-19 severity and survival but also infers what clinical features are more impactful, which makes our approach a useful guide for clinicians for prioritization of best-fit therapeutics for a given cohort of patients. Moreover, with weighted gene network analysis, we are able to provide insights into gene networks that have a significant association with COVID-19 severity and clinical features. Finally, we have demonstrated the importance of clinical biomarkers in identifying high-risk patients and predicting disease progression.

4 September 2026 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
SGStefano Gaburro
Stefano Gaburro
BBBrian Berridge
Brian Berridge
NKNicholas W. Kelley
Nicholas W. Kelley
EKEckhard von Keutz
Eckhard von Keutz
MFMarc Ferrer
Marc Ferrer
SBSzczepan Baran
Szczepan Baran